Second Annual
Cutaneous Malignancies Forum
Contemporary Issues in Effective Diagnosis and Treatment

November 4 - 5, 2020

Virtual Event

Jointly Provided by:

In Association With:

  • 00


  • 00


  • 00


  • 00



(Eastern Time)

I Introduction – Goals of the meeting

Co-Chairs: Sancy Leachman, MD, PhD/Mohammed Kashani-Sabet, MD

5:30 – 5:40 PM

II Melanoma Session

Epidemiological state of the art

Laura Ferris, MD, PhD

5:40 - 6:00 PM

Melanoma detection: Different tools for different populations

Sancy Leachman, MD, PhD

6:00 - 6:20 PM

Impacts of COVID shelter-in-place

Rebecca Hartman, MD

6:20 - 6:40 PM

Reanalysis of the prognostic importance of mitotic rate in melanoma

Mohammed Kashani-Sabet, MD

6:40 - 7:00 PM

The surgeon/oncologist role in treatment and follow-up

Merrick Ross, MD

7:00 - 7:20 PM

Best medical adjuvant and neoadjuvant therapy for melanoma

John Kirkwood, MD

7:20 - 7:40 PM

Melanoma case study pro/con discussion: Molecular profiling, treatment, and management

Mohammed Kashani-Sabet, MD/Sancy Leachman, MD, PhD/Laura Ferris, MD, PhD/Rebecca Hartman, MD/John Kirkwood, MD

7:40 - 8:00 PM

III Cutaneous T-Cell Lymphoma

Introduction to CTCL: Dermatopathology and Diagnosis

Michi Shinohara, MD

8:00 - 8:20 PM

CTCL case study presentations and discussion including ARS

Youn Kim, MD and Michi Shinohara, MD

8:20 - 8:55 PM

Sessions Conclude/Wrap-Up

Mohammed Kashani-Sabet, MD

8:55 - 9:00 PM

IV Keratinocytic Carcinomas Session


Sancy Leachman, MD, PhD/Mohammed Kashani-Sabet, MD

5:20 - 5:30 PM

Epidemiology and data-based management of keratinocytic carcinomas

Maryam Asgari, MD

5:30 - 5:50 PM

Topical and systemic therapies for basal cell carcinoma

Ervin Epstein, MD

5:50 - 6:10 PM

High-risk squamous cell carcinoma: Surgical treatment and molecular diagnostics

Anna Bar, MD

6:10 - 6:30 PM

Systemic therapy for larger, inoperable keratinocytic carcinomas

Michael R. Migden, MD

6:30 - 6:50 PM

Staging and therapy of cSCC

Guilherme Rabinowits, MD

6:50 - 7:10 PM

cSCC case study presentations and discussion

Guilherme Rabinowits, MD/ Maryam Asgari, MD/Ervin Epstein, MD/Michael Migden, MD/Anna Bar, MD

7:10 - 7:30 PM

V Merkel Cell Carcinoma Session

Clinical and scientific advances in MCC

Isaac Brownell, MD, PhD

7:30 - 7:50 PM

Detection and surveillance of MCC

Manisha Thakuria, MD

7:50 - 8:10 PM

Surgical treatment of MCC

Mark Faries, MD

8:10 - 8:30 PM

Case study presentations and discussion

Mark Faries, MD/Isaac Brownell, MD, PhD/Manisha Thakuria

8:30 - 8:50 PM

Sessions Conclude/Wrap Up

Sancy Leachman, MD, PhD

8:50 - 9:00 PM


(Eastern Time)

Identifying Appropriate Patients With Advanced CSCC Who May Benefit From Systemic Therapy (Non-CE/CME)

Speaker: Mark Agulnik, MD, CM
City of Hope Medical Center
Duarte, CA

Sponsored by: Regeneron

7:00 PM - 8:00 PM


avatar Sancy Leachman, MD, PhD

Professor of Dermatology Oregon Health & Science University
Chair, Department of Dermatology
Director, Melanoma Research Program
Knight Cancer Institute
Portland, OR

avatar Mohammed Kashani-Sabet, MD

Director, Melanoma Program
Senior Scientist
California Pacific Medical Center Research Institute
San Francisco, CA


avatar Maryam Asgari, MD

Professor of Dermatology
Harvard Medical School
Boston, MA

avatar Anna Bar, MD

Associate Professor of Dermatology
Oregon Health & Science University School of Medicine
Portland, OR

avatar Isaac Brownell, MD, PhD

Head, Cutaneous Development and Carcinogenesis Section
Attending Physician
Bethesda, MD

avatar Ervin Epstein, MD

Sutter Health
Oakland, CA

avatar Mark Faries, MD

Professor of Surgery
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA

avatar Laura Ferris, MD, PhD

Associate Professor
University of Pittsburgh Clinical and Translational Science Institute
Director of Clinical Trials
University of Pittsburgh
Pittsburgh, PA

avatar Rebecca Hartman, MD, MPH

Instructor in Dermatology
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

avatar Youn Kim, MD

The Joanne and Peter Haas, Jr, Professor for Cutaneous Lymphoma Research
Professor of Medicine/Dermatology
Director, Multidisciplinary Cutaneous Lymphoma Clinic/Program
Stanford University Medical Center
Stanford, CA

avatar John Kirkwood, MD

Professor of Medicine, Dermatology and Clinical and Translational Science
University of Pittsburgh
Director, Melanoma Center
University of Pittsburgh Hillman Cancer Center
Pittsburgh, PA

avatar Michael Migden, MD

Professor, Department of Dermatology
Professor, Department of Head and Neck Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

avatar Guilherme Rabinowits, MD

Associate Professor of Medicine
Physician lead, head and neck medical oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, FL

avatar Merrick Ross, MD

Charles M. McBride Distinguished Professorship in Surgical Oncology
Chief, Melanoma Section
The University of Texas MD Anderson Cancer Center
Houston, TX

avatar Michi Shinohara, MD

Associate Professor
Associate Chief, Division of Dermatology
Michael W. Piepkorn Endowed Chair in Dermatologic Research
Director, Dermatology Inpatient Consultation Service
University of Washington
Seattle, WA

avatar Manisha Thakuria, MD

Director, Merkel Cell Carcinoma Clinic
Instructor in Dermatology
Dana-Farber/Brigham and Women’s Cancer Center
Assistant Professor of Dermatology
Harvard Medical School
Boston, MA


  • Melanoma
  • Keratinocytic Carcinomas
  • Topical and systemic therapies for basal cell carcinoma
  • Cutaneous T-Cell Lymphoma
  • Merkel Cell Carcinoma


Learning Objectives

At the conclusion of this activity, participants will be better able to:

  • Assess the clinical potential of novel agents in MDS
  • Personalize treatment strategies and utilize novel therapies for patients with ALL
  • Deliberate on the role for newer therapies in the AML treatment paradigm, especially for older patients
  • Manage toxicities of CAR T-cell therapy in ALL
  • Design strategies to integrate new therapies into clinical practice for treating MDS, ALL, and AML

Accreditation and Certification

The proposed activity will be planned and implemented in accordance with the accreditation requirements and policies of Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center Commission on Accreditation (ANCC) through the joint providership of Postgraduate Institute for Medicine (PIM) and Global Academy for Medical Education. PIM will certify all activities for continuing education credit as defined below.

logo PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Certification
PIM designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits.

Continuing Pharmacy Education
PIM designates this continuing education activity for 6.5 contact hour(s) (6.5 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education
PIM awards a maximum of 6.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Continuing Physician Assistants Education
PIM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.5 credits AAPA Category 1 CME credits.

location icon

Global Academy for Medical Education LLC.
7 Century Drive, Suite 301
Parsippany NJ 07054

email icon

MedscapeLive Support
Phone: 877-671-1602
Email: [email protected]